ArticleCancer cell2025
Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer.
Abstract read
In one paragraph
Article in Cancer cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- VISTA+ Neutrophils Contribute to Platinum Resistance by Suppressing CD8+ T Cells in High-Grade Serous Ovarian Cancer.Cancer immunology research · 2026Article
- Spatiotemporal immune heterogeneity and precision immunotherapy for ovarian cancer.Clinical and translational medicine · 2026Review
- The chemotherapy-induced senescence-associated secretome promotes cell detachment and metastatic dissemination through metabolic reprogramming.Nature aging · 2026Article
- Combinatorial Delivery of Low-Dose Radiotherapy and Immunotherapy to Patients with Immune-Excluded Tumors Enhances CD8+ T-cell Functionality.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Article
- Rethinking ovarian cancer III: the past decade and future directions.Nature reviews. Cancer · 2026Review
- A prognostic model based on ScissorTranslational cancer research · 2026Article
- TAMs in the Gynecological Tumor Microenvironment: Insights from Cross-Cancer Studies for Immunotherapy.Cancers · 2026Review
- Combination of Tripterygium glycosides and Lactobacillus paracasei sensitises epithelial ovarian cancer to cisplatin via downregulating Keap1-Nrf2-GPX4 signalling pathway.Cellular & molecular biology letters · 2026Article
- Targeting Monocytes and Their Derivatives in Ovarian Cancer: Opportunities for Innovation in Prognosis and Therapy.Cancers · 2026Review
- Macrophage polarization in gynecologic malignancies: key signaling pathways and clinical perspectives.Frontiers in immunology · 2026Review
- Neoadjuvant chemotherapy-induced immune remodeling in ovarian cancer: implications for TIL dynamics and combination immunotherapy.Frontiers in immunology · 2026Review
- The immune microenvironment: a key regulator of ovarian function during ovarian aging.Frontiers in immunology · 2026Review
- Ovarian cancer drives TLR5-dependent expansion of myeloid progenitors through systemic ligand dissemination.Journal of leukocyte biology · 2025Article
- Epigenetic Regulation of Immune Responses in Endocrine-Related Cancers and Its Role in Immunotherapy.Cancers · 2025Review
- Tissue specificity and chromosomal alterations shape divergent immune programs in HRD tumors.bioRxiv : the preprint server for biology · 2025Article
- Decoding inflammatory regulation in ovarian cancer at single-cell resolution.Frontiers in immunology · 2025Review
- Macrophage Polarization in the Tumor Microenvironment of Hepatocellular Carcinoma: From Mechanistic Insights to Translational Therapies.Cancer control : journal of the Moffitt Cancer CenterReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
42 authors.
Eleonora GhisoniDepartment of Oncology, Lausanne University Hospital; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL); Agora Cancer Research Center, Lausanne, Switzerland; Immuno-oncology Service, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.
Fabrizio BenedettiDepartment of Oncology, Lausanne University Hospital; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL); Agora Cancer Research Center, Lausanne, Switzerland.
Aspram MinasyanDepartment of Oncology, Lausanne University Hospital; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL); Agora Cancer Research Center, Lausanne, Switzerland.
Mathieu DesbuissonDepartment of Oncology, Lausanne University Hospital; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL); Agora Cancer Research Center, Lausanne, Switzerland.
Paula CunneaDivision of Cancer, Department of Surgery and Cancer, Imperial College London, London W12 0HS, UK.
Alizée J GrimmDepartment of Oncology, Lausanne University Hospital; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL); Agora Cancer Research Center, Lausanne, Switzerland.
Noémie FahrDepartment of Oncology, Lausanne University Hospital; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL); Agora Cancer Research Center, Lausanne, Switzerland.
Charlotte CaptDepartment of Oncology, Lausanne University Hospital; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL); Agora Cancer Research Center, Lausanne, Switzerland.
Nicolas RayrouxDepartment of Oncology, Lausanne University Hospital; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL); Agora Cancer Research Center, Lausanne, Switzerland.
Flavia De CarloDepartment of Oncology, Lausanne University Hospital; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL); Agora Cancer Research Center, Lausanne, Switzerland.
Doga C GulhanDepartment of Oncology, Lausanne University Hospital; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL); Agora Cancer Research Center, Lausanne, Switzerland; Massachusetts General Hospital Cancer Center and Harvard Medical School Department of Medicine, Boston, MA, USA.
Julien DagherUnit of Translational Oncopathology, Institute of Pathology, Lausanne University Hospital, Lausanne, Switzerland.
David BarrasDepartment of Oncology, Lausanne University Hospital; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL); Agora Cancer Research Center, Lausanne, Switzerland.
Matteo MorottiDepartment of Oncology, Lausanne University Hospital; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL); Agora Cancer Research Center, Lausanne, Switzerland.
Juan A Marín-JiménezCancer Immunotherapy Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Bovannak Stewen ChapDepartment of Oncology, Lausanne University Hospital; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL); Agora Cancer Research Center, Lausanne, Switzerland.
Tania SantoroDepartment of Oncology, Lausanne University Hospital; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL); Agora Cancer Research Center, Lausanne, Switzerland.
Giulia SpagnolDepartment of Women and Children's Health, Unit of Gynecology and Obstetrics, University of Padua, Padua, Italy.
Mapi FleuryImmuno-oncology Service, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.
Katerina FortisCenter of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.
Julien DorierBioinformatics Competence Center, University of Lausanne, Lausanne, Switzerland.
Mary K TownsendDivision of Oncological Sciences, OHSU Knight Cancer Institute, Portland, OR, USA.
Stephanie TissotCenter of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.
Sylvie RusakiewiczCenter of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.
Humberto J FerreiraDepartment of Oncology, Lausanne University Hospital; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL); Agora Cancer Research Center, Lausanne, Switzerland.
Anne I KraemerDepartment of Oncology, Lausanne University Hospital; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL); Agora Cancer Research Center, Lausanne, Switzerland.
Michal Bassani-StenbergDepartment of Oncology, Lausanne University Hospital; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL); Agora Cancer Research Center, Lausanne, Switzerland.
Elizabeth M SwisherDepartment of Obstetrics/Gynecology, University of Washington, Seattle, WA, USA.
Lana A KandalaftDepartment of Oncology, Lausanne University Hospital; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL); Agora Cancer Research Center, Lausanne, Switzerland; Center of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.
Spyridon A MastroyannisOvarian Cancer Research Center, University of Pennsylvania, Philadelphia, PA 19104, USA.
Kathleen T MontoneDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Daniel J PowellDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Susana BanerjeeThe Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK.
Kathryn L TerryObstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Shelley S TworogerDivision of Oncological Sciences, OHSU Knight Cancer Institute, Portland, OR, USA.
Mikaël J PittetDepartment of Oncology, Lausanne University Hospital; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL); Agora Cancer Research Center, Lausanne, Switzerland; Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
Janos L TanyiOvarian Cancer Research Center, University of Pennsylvania, Philadelphia, PA 19104, USA.
George CoukosDepartment of Oncology, Lausanne University Hospital; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL); Agora Cancer Research Center, Lausanne, Switzerland; Immuno-oncology Service, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.
Melissa A MerrittThe Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
Christina FotopoulouDivision of Cancer, Department of Surgery and Cancer, Imperial College London, London W12 0HS, UK.
Jose R Conejo-GarciaDepartment of Integrative Immunobiology, Duke School of Medicine, Durham, NC 27707, USA.
Denarda Dangaj LanitiDepartment of Oncology, Lausanne University Hospital; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL); Agora Cancer Research Center, Lausanne, Switzerland. Electronic address: denarda.dangaj@chuv.ch.
Funding
Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, TAMIMI, RULLA M · 2000 to 2019
$77.8MLife Course Cancer Epidemiology Cohort in WomenU01CA176726 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI ELIASSEN, A. HEATHER, WILLETT, WALTER C. · 2018 to 2025
$22.4MLong Term Multidisciplinary Study of Cancer in Women: The Nurses Health StudyUM1CA186107 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, STAMPFER, MEIR · 2014 to 2023
$22.3MChanging Contraceptive Patterns and Ovarian Cancer RiskR01CA258679 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI TERRY, KATHRYN L. · 2021 to 2025
$2.5MNCI NIH HHS P01 CA087969NCI NIH HHS R01 CA258679NCI NIH HHS U01 CA176726NCI NIH HHS UM1 CA186107
Abstract
Immunotherapy has shown limited success in recurrent ovarian cancer (OC), with prognostic insights largely derived from treatment-naive tumors. We analyzed 697 tumor samples (566 primary and 131 recurrent) from 595 OC patients across five independent cohorts, capturing tumor-infiltrating lymphocytes (TILs) heterogeneity and identifying four immune phenotypes linked to prognosis and TIL:myeloid networks driving malignant progression. We found that in preclinical mouse models, mirroring inflamed human OCs, the recurrent Brca1
Indexed as
Lymphocytes, Tumor-InfiltratingMyeloid CellsNeoplasm Recurrence, LocalOvarian NeoplasmsAnimalsBRCA1 ProteinDendritic CellsFemaleHumansMicePrognosisTumor MicroenvironmentBRCA1 ProteinBRCA1 protein, humanimmune phenotypemyeloid-T cell networksovarian cancerPGE(2) signalingrecurrenceTREM2tumor microenvironment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.